EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Theriva Biologics's enterprise value is $-11.24 Mil.
Theriva Biologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.30 Mil. Therefore, Theriva Biologics's EV-to-EBITDA for today is 0.53.
The historical rank and industry rank for Theriva Biologics's EV-to-EBITDA or its related term are showing as below:
TOVX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.9 Med: -0.89 Max: 2.35
Current: 0.53
During the past 13 years, the highest EV-to-EBITDA of Theriva Biologics was 2.35. The lowest was -26.90. And the median was -0.89.
TOVX's EV-to-EBITDA is ranked better than 78.81% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs TOVX: 0.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Theriva Biologics's stock price is $0.3769.
Theriva Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.160. Therefore, Theriva Biologics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Theriva Biologics EV-to-EBITDA Historical Data
The historical data trend for Theriva Biologics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theriva Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theriva Biologics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Theriva Biologics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Theriva Biologics's EV-to-EBITDA falls into.
Theriva Biologics EV-to-EBITDA Calculation
Theriva Biologics's EV-to-EBITDA for today is calculated as:
Theriva Biologics's current Enterprise Value is $-11.24 Mil.
Theriva Biologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Theriva Biologics's PE Ratio for today is calculated as:
Theriva Biologics's share price for today is $0.3769.
Theriva Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Theriva Biologics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Theriva Biologics (Theriva Biologics) Business Description
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TOVX has been successfully added to your 